Premier Biomedical, Inc. (BIEI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Premier Biomedical, Inc. (BIEI) with AI Score 46/100 (Weak). Premier Biomedical, Inc. is a research-based company focused on the development of medical products. The company's primary focus is on hemp oil-based topical pain relief products. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Premier Biomedical, Inc. (BIEI) Healthcare & Pipeline Overview
Premier Biomedical, Inc. is a research-based pharmaceutical company specializing in the development and distribution of hemp oil-based topical pain relief products. Founded in 2010, the company operates in the competitive medical sector, focusing on innovative pain management solutions, while navigating the regulatory landscape of the pharmaceutical industry.
Investment Thesis
Premier Biomedical, Inc. presents a high-risk, high-reward investment profile due to its early-stage nature and focus on hemp oil-based pain relief products. With a market capitalization of $0.00B and a negative P/E ratio of -5.77, the company's financial metrics reflect its current lack of profitability. The company's beta of 0.06 suggests low volatility compared to the overall market. Key catalysts include potential breakthroughs in their research and development efforts, successful navigation of regulatory approvals, and expansion of their distribution network. However, potential risks include the inherent uncertainty of pharmaceutical research, competition from larger players in the pain relief market, and the evolving regulatory landscape surrounding hemp-derived products. The investment thesis hinges on Premier Biomedical's ability to successfully commercialize its products and achieve profitability in a rapidly changing market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- P/E Ratio of -5.77 reflects current unprofitability, common for research-based pharmaceutical companies in early stages.
- Beta of 0.06 suggests the stock price has low volatility compared to the overall market.
- Focus on hemp oil-based topical pain relief products positions the company in a growing market segment.
- Small team of 4 employees indicates a lean operational structure and potential for scalability.
Competitors & Peers
Strengths
- Focus on natural hemp oil-based pain relief.
- Research-based approach to product development.
- Lean operational structure with low overhead.
- Potential for innovation in a growing market.
Weaknesses
- Limited financial resources and market capitalization.
- Small team and limited operational capacity.
- Dependence on a single product category.
- Lack of established brand recognition.
Catalysts
- Upcoming: Potential breakthroughs in research and development of new pain relief products.
- Upcoming: Successful navigation of regulatory approval processes for its products.
- Ongoing: Expansion of the company's distribution network and market reach.
- Ongoing: Increasing consumer demand for natural and alternative pain relief solutions.
- Ongoing: Strategic partnerships with established pharmaceutical companies or distributors.
Risks
- Potential: Competition from established pharmaceutical companies with greater resources.
- Potential: Evolving regulatory landscape for hemp-derived products and potential changes in regulations.
- Potential: Uncertainty of research and development outcomes and potential for failure.
- Ongoing: Limited financial resources and market capitalization.
- Ongoing: Dependence on a single product category and lack of diversification.
Growth Opportunities
- Expansion of Product Line: Premier Biomedical can leverage its expertise in hemp oil-based products to develop new formulations and delivery methods. The market for topical pain relief is projected to reach $14.1 billion by 2027, offering a significant opportunity for growth. By diversifying its product line to include creams, gels, and patches, the company can cater to a wider range of consumer preferences and needs. Successful product line expansion would require additional research and development, as well as effective marketing strategies to reach target consumers.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or distributors can provide Premier Biomedical with access to broader markets and distribution channels. The global pharmaceutical distribution market is valued at over $700 billion, highlighting the potential benefits of strategic partnerships. By partnering with a larger company, Premier Biomedical can leverage their existing infrastructure and expertise to accelerate market penetration and increase sales. This strategy would require careful negotiation and alignment of interests to ensure mutual benefit.
- Targeted Marketing Campaigns: Implementing targeted marketing campaigns can help Premier Biomedical reach specific consumer segments and increase brand awareness. The digital advertising market for healthcare products is growing rapidly, offering opportunities to reach consumers through online channels. By focusing on specific demographics and pain conditions, the company can tailor its messaging and increase the effectiveness of its marketing efforts. Successful marketing campaigns would require a deep understanding of consumer behavior and preferences.
- Research and Development: Investing in further research and development can lead to the discovery of new and innovative pain relief solutions. The pharmaceutical industry is characterized by continuous innovation, and companies that invest in R&D are more likely to develop breakthrough products. By focusing on novel drug delivery systems and formulations, Premier Biomedical can differentiate itself from competitors and gain a competitive advantage. This strategy would require significant investment in research infrastructure and personnel.
- Regulatory Approvals: Obtaining regulatory approvals for its products can significantly enhance Premier Biomedical's credibility and market access. The regulatory approval process for pharmaceutical products is rigorous and time-consuming, but it can provide a significant competitive advantage. By successfully navigating the regulatory landscape, the company can demonstrate the safety and efficacy of its products and gain access to larger markets. This strategy would require a strong understanding of regulatory requirements and a commitment to compliance.
Opportunities
- Expansion into new product lines and markets.
- Strategic partnerships with larger companies.
- Increased consumer demand for natural pain relief solutions.
- Potential for regulatory approvals and market access.
Threats
- Competition from established pharmaceutical companies.
- Evolving regulatory landscape for hemp-derived products.
- Uncertainty of research and development outcomes.
- Potential for adverse side effects or safety concerns.
Competitive Advantages
- Focus on hemp oil-based products in a growing market.
- Proprietary formulations and research in pain relief.
- First-mover advantage in specific niche markets.
About BIEI
Premier Biomedical, Inc., established on May 10, 2010, by Mitchell S. Felder, is a research-driven company dedicated to the discovery and development of medical products. Headquartered in Knoxville, TN, the company's primary focus lies in the creation and distribution of topical pain relief products derived from hemp oil. This strategic direction allows Premier Biomedical to tap into the growing market for alternative pain management solutions. The company operates with a small team of four employees, managed by David Caplan, indicating a lean operational structure. Premier Biomedical's business model centers around research and development, aiming to innovate in the pharmaceutical sector. Their current emphasis on hemp oil-based products aligns with increasing consumer interest in natural and alternative remedies. However, as a smaller player in the pharmaceutical industry, Premier Biomedical faces challenges related to research funding, regulatory approvals, and market competition. Premier Biomedical's success depends on its ability to successfully navigate the regulatory landscape, secure funding for ongoing research, and effectively market its products to a broad consumer base. The company's size and focus suggest a niche strategy, targeting specific segments within the pain relief market.
What They Do
- Develops medical products focused on pain relief.
- Specializes in hemp oil-based topical pain relief products.
- Conducts research to discover new medical solutions.
- Distributes its products to consumers.
- Innovates in the pharmaceutical sector with alternative remedies.
- Aims to provide natural pain management options.
Business Model
- Focuses on research and development of medical products.
- Generates revenue through the sale of hemp oil-based topical pain relief products.
- Employs a lean operational structure with a small team.
Industry Context
Premier Biomedical, Inc. operates within the medical pharmaceutical industry, specifically targeting the pain relief market. This sector is characterized by intense competition, stringent regulatory requirements, and significant research and development costs. The increasing demand for alternative and natural pain relief solutions, estimated to reach billions of dollars by 2028, presents a growth opportunity for companies like Premier Biomedical. However, they face competition from established pharmaceutical giants and other emerging players in the hemp-derived products market. Success in this industry requires innovation, effective marketing, and the ability to navigate the complex regulatory landscape.
Key Customers
- Individuals seeking topical pain relief.
- Consumers interested in natural and alternative remedies.
- Patients looking for non-prescription pain management options.
Financials
Chart & Info
Premier Biomedical, Inc. (BIEI) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Nov 14, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Nov 4, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 17, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BIEI.
Price Targets
Wall Street price target analysis for BIEI.
MoonshotScore
What does this score mean?
The MoonshotScore rates BIEI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David Caplan
CEO
David Caplan serves as the CEO of Premier Biomedical, Inc., overseeing the company's strategic direction and operations. His background includes experience in managing small teams and guiding research-based initiatives. Caplan's leadership is crucial for navigating the challenges of the pharmaceutical industry and driving the company's growth in the competitive market. His expertise in business development and strategic planning is essential for Premier Biomedical's success.
Track Record: Under David Caplan's leadership, Premier Biomedical has focused on developing and distributing hemp oil-based topical pain relief products. Key milestones include expanding the company's product line and establishing partnerships with distributors. Caplan's strategic decisions have been instrumental in positioning the company for future growth and success in the evolving pharmaceutical market.
BIEI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Premier Biomedical may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low liquidity and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and investor protection.
- Higher risk of business failure or bankruptcy.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal proceedings.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Company registration and legal compliance.
- Active website and investor relations.
- Independent audits of financial statements (if available).
- Press releases and public announcements.
- Management team with relevant experience.
Premier Biomedical, Inc. Stock: Key Questions Answered
What does Premier Biomedical, Inc. do?
Premier Biomedical, Inc. is a research-based company focused on developing and distributing medical products, primarily hemp oil-based topical pain relief products. The company conducts research to discover new medical solutions and aims to provide natural pain management options to consumers. Their business model centers around innovating in the pharmaceutical sector with alternative remedies, targeting individuals seeking topical pain relief and consumers interested in natural products.
What do analysts say about BIEI stock?
As of 2026-03-17, there is no available analyst coverage for Premier Biomedical, Inc. due to its micro-cap status and OTC listing. The company's financial metrics, including a market cap of $0.00B and a negative P/E ratio, reflect its early-stage nature and current lack of profitability. Investors should conduct their own due diligence and consider the risks associated with investing in OTC-listed companies with limited financial disclosure.
What are the main risks for BIEI?
The main risks for Premier Biomedical, Inc. include competition from established pharmaceutical companies, the evolving regulatory landscape for hemp-derived products, and the uncertainty of research and development outcomes. The company's limited financial resources and dependence on a single product category also pose significant risks. Investors should be aware of the potential for price manipulation and fraud associated with OTC-listed companies.
How does Premier Biomedical, Inc. navigate regulatory approval processes?
Premier Biomedical, Inc.'s strategy for navigating regulatory approval processes is currently unknown due to limited available information. As a research-based company focused on medical products, regulatory approvals are critical for commercializing its products. The company's success depends on its ability to comply with FDA regulations and demonstrate the safety and efficacy of its pain relief solutions. Further information is needed to assess Premier Biomedical's regulatory track record and compliance strategy.
What is Premier Biomedical, Inc.'s drug pipeline status?
As of 2026-03-17, specific details regarding Premier Biomedical, Inc.'s drug pipeline status are not publicly available. The company's primary focus is on hemp oil-based topical pain relief products, but information on clinical trials or upcoming catalysts related to drug development is currently unknown. Investors should seek further information from the company regarding its research and development efforts and potential pipeline candidates.
What are the key factors to evaluate for BIEI?
Premier Biomedical, Inc. (BIEI) currently holds an AI score of 46/100, indicating low score. Key strength: Focus on natural hemp oil-based pain relief.. Primary risk to monitor: Potential: Competition from established pharmaceutical companies with greater resources.. This is not financial advice.
How frequently does BIEI data refresh on this page?
BIEI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BIEI's recent stock price performance?
Recent price movement in Premier Biomedical, Inc. (BIEI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on natural hemp oil-based pain relief.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Premier Biomedical, Inc. due to its OTC listing and micro-cap status.
- Financial data and analyst coverage are scarce, requiring investors to conduct thorough due diligence.
- The company's future performance is highly dependent on the success of its research and development efforts and its ability to navigate the regulatory landscape.